Home
overview

In the last fifty years, the pharmacologic therapies available to alleviate pain have changed remarkably little. With this lull in the delivery of novel analgesics, SMi is proud to present its 8th Annual Pain Therapeutics Conference. This conference will gather the key industry experts to determine how today’s challenges in pain therapeutics can be overcome, covering pressing issues such as combating neuropathic pain and assessing novel targets for pain relief.

Groundbreaking developments and updates to be covered include:
  • HOT NEW TARGETS for effective pain relief
  • SUCCESSFUL AND NOVEL approaches to neuropathic and neurological pain
  • NEW AND EVOLVING ANALGESICS in development.
  • THE RELEVANCE of translational pharmacology to neurological pain
  • THE IMPORTANCE of animal pain models
Covering essential updates from the past 12 months, this conference will be delivered by an excellent panel of speakers including:
  • Dr Linda Surh, Director, CEDD Global Regulatory Affairs, GlaxoSmithKline
  • Dr Tony Ho, Senior Director, Clinical Neurosciences, Merck
  • Dr Joachim Scholpp, Associate Head Therapeutic Area CNS, Boehringer-Ingelheim
  • Dr Aldemar Degroot, Scientist, Exploratory Development Department, Astellas
The continual and consistent success of the SMi Group’s Pain Therapeutics Conferences has established its reputation as a cornerstone conference in the field. 2008’s Pain Therapeutics Conference cannot afford to be missed to keep up to date with the most cutting-edge, revolutionary developments.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Linda Surh

Linda Surh, Director, CEDD Global Regulatory Affairs , GlaxoSmithKline

9:10 OUTCOME OF TREATMENT IN NEUROPATHIC PAIN IN CLINICAL PRACTICE - ITS IMPLICATION FOR DRUG DEVELOPMENT AND STUDY DESIGN

Rolf  Karlsten

Rolf Karlsten, Medical Science Director, AstraZeneca

Awaiting presentation details

9:50 ACCELERATING THE DEVELOPMENT OF PAIN MOLECULES THROUGH EARLY CLINICAL DEVELOPMENT

John Connell

John Connell, Director, Clinical Pharmacodynamics & Project Management, Icon Development Solutions

  • Translating preclinical signals into efficacy in patients
  • Do volunteer models reflect chronic pain states?
  • Strategies for the use of imaging in drug discovery and development

10:30 Morning Coffee

11:00 HOW TO ADDRESS THE REGULATORY REALITIES OF THE DEVELOPMENT OF CANNABINOID MEDICINES

Stephen Wright

Stephen Wright, Research & Development Director, GW Pharmaceuticals plc

  • There is a substantial need for a new class of analgesic medicine
  • Anecdotal evidence provides a compelling vernacular case for the efficacy of cannabinoids
  • Pharmacologic findings argue for synergy between different cannabinoids in providing clinically useful analgesia
  • Clinical data so far support the proposition that cannabinoids may be more effective in concert than when used alone
  • A plant extract (botanical drug product) offers an appropriate regulatory route to developing a medicine which uses this approach in a development program for a new analgesic
  • Sativex is an example of the only new class of analgesic approved for prescription use in the last decade
  • 11:40 NOVEL CLINICAL APPROACHES TO INFLAMMATORY AND NEUROPATHIC PAIN

    Praveen Anand

    Praveen Anand, Professor, Clinical Neurology, Imperial College London

    ·              Evolving clinical concepts and translational models
    ·              Novel drug target validation in chronic pain states
    ·              Relating molecular and genetic mechanisms to clinical manifestations
    ·              Recent developments in neuropathic pain analgesics and preventive strategies

    12:20 Networking Lunch

    13:50 CHALLENGES OF DEVELOPING NEW COMPOUNDS FOR NEUROPATHIC PAIN

    Joachim Scholpp

    Joachim Scholpp, Associate Therapeutic Assc Head, Boehringer-Ingelheim

  • Performance of currently available drugs / the medical need
  • Current clinical development scenario
  • New targets: early clinical decision making?
  • Efficacy: what can we expect in the clinic?
  • Target population: how to define the right population?
  • Clinical development approaches: innovative strategies?
  • 14:30 PANEL DISCUSSION - WHY HAVE WE NOT BEEN ABLE TO DELIVER NOVEL ANALGESICS

    Linda Surh

    Linda Surh, Director, CEDD Global Regulatory Affairs , GlaxoSmithKline

    Praveen Anand

    Praveen Anand, Professor, Clinical Neurology, Imperial College London

    Chas Bountra

    Chas Bountra, Chief Scientist, University Of Oxford

    15:10 Afternoon Tea

    15:40 ION CHANNEL-ACCESSORY PROTEIN INHIBITORS AS THERAPEUTICS FOR NEUROPATHIC AND INFLAMMATORY PAIN

    Roland Kozlowski

    Roland Kozlowski, Chief Executive Officer, Lectus Therapeutics Ltd

  • Kv channel accessory proteins as drug targets for neuropathic and inflammatory pain
  • Cav channel accessory proteins as drug targets for neuropathic pain
  • LEPTICS® platform for the development of novel pain therapeutics
  • Validation of  ion channel/accessory protein inhibitors for neuropathic and inflammatory pain
  • 16:20 DEVELOPMENT OF A BLOCKING ANTIBODY TO NERVE GROWTH FACTOR AS A PAIN THERAPEUTIC

    Dave Shelton

    Dave Shelton, Senior Director, Pfizer

    • NGF a well-known potential target
    • Various approaches for targeting NGF
    • Characteristics of a blocking, humanized antibody
    • Preclinical results and early clinical findings

    17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Tony Ho

    Tony Ho, Senior Director, Merck Research Laboratories

    9:10 ENHANCED TRANMISSION AT CANNABINOID RECEPTORS AND NEUROPATHIC PAIN

    Aldemar Degroot

    Aldemar Degroot, Translational Scientist, Astellas Pharma Europe

  • Cannabinoid agonists
  • CB1 and CB2 receptors
  • Wndocannabinoids
  • FAAH inhibitors
  • Future prospects
  • 9:50 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

    Tony Ho

    Tony Ho, Senior Director, Merck Research Laboratories

  • The therapeutic profile of MK-0974 for the acute treatment of migraines
  • Profiling the safety and efficacy of MK-0974
  • Revolutionising migraine treatment since the first triptan was approved
  • The mechanisms of pain relief by MK-0974
  • 10:30 Morning Coffee

    11:00 TARGETING VOLTAGE-GATED SODIUM CHANNELS FOR PAIN THERAPY

    Jeff Clare

    Jeff Clare, Director, Millipore

    • Sodium channels as pain targets
    • Functional assays for selectivity profiling
    • Comparison of human and rat Nav1.8

    11:40 TRP CHANNELS AS TARGETS FOR PAIN RELIEF

    Lisa Broad

    Lisa Broad, Senior, In Vitro Pharmacology, Pain-Migraine DHT, Neuroscience, Eli Lilly & Company

  • Background on TRPV1 polymodal functionality.
  • Background on TRPV1 pharmacology: agonists, antagonists, and other modulators.
  • Which preclinical models better predict TRPV1 modulators efficacy.
  • Development status, competition, risks.
  • Magic bullet or tailored therapy?
  • 12:20 Networking Lunch

    13:50 TARGETING ACID SENSING ION CHANNELS FOR THE TREATMENT OF PAIN

    Gilles Dubé

    Gilles Dubé, Director of Pharmacology, PainCeptor Pharma Corporation

    ·         Pain and tissue acidosis

    ·         Overview of the biology and pharmacology of ASICs

    ·         ASICs antagonists and analgesia – POC in animal models and future perspectives

    14:30 SODIUM CHANNEL MODULATORS AS ANALGESICS

    Steve England

    Steve England, Associate Research Fellow, Pfizer

    • Sodium channels involved in pain signalling
    • Current sodium channel modulators used in clinical practice
    • Emerging pharmacology in the drug class

    15:10 Afternoon Tea

    15:40 TRPV3 ANTAGONISTS IN PAIN MANAGEMENT - GENERATION NEXT?

    Neelima Khairatkar-Joshi

    Neelima Khairatkar-Joshi, Vice President, Glenmark Research Centre

  • TRPV3 Receptor and Target Biology
  • TRPV3 in pain signaling
  • Identification of TRPV3 receptor antagonist hits through screening
  • In vitro proof on concept – potent, selective and multimodal blockage of TRPV3 receptor activation by selected hits
  • Efficacy in various animal models of pain
  • Concerns??
  • 16:20 ASPECTS OF THE P2X7 PROGRAM

    Simon  Cruwys

    Simon Cruwys, Team Leader, Research and Development, Respiratory and Inflammation, AstraZeneca

    17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.